Visions - Winter 2008 - (Page 11)

Oxford’s mission is clear: to deliver flexible financial solutions that leverage the clients’ equity, while empowering them with the resources needed to foster innovation and growth. laborations for pharmaceuticals and medical devices, and equity investments. From time to time, Oxford has been invited to make small equity investments by its customers. Currently, Oxford has investments in two companies,Tengion and MAP Pharmaceuticals. Tengion is a regenerative medicine company that can grow new organs for a patient from the patient’s own cells, while MAP Pharmaceuticals uses its technology to deliver innovative drugs such as inhalants. These investments cement important relationships and enhance Oxford’s reputation in the industry. “We are extremely pleased to have Oxford as part of our portfolio, and we look forward to another year of growth in 2008,” said SCOA’s John Degen, senior director of business investment. “We’ve accomplished all the goals of our original business plan that we established in 2004, and we see much more opportunity ahead.” For more information, contact Shelly Davis at sdavis@oxfordfinance.com. Sumitomo Corporation of America 11

Table of Contents Feed for the Digital Edition of Visions - Winter 2008

Visions - Winter 2008 Contents Sumitomo Corporation and Wal-Mart Continue To Strengthen Their Bond Pacific Summit Energy Experiences Profit and Expansion SCOA Enters Cosmetics Industry By Acquiring Presperse LLC TBC Private Brands Never “Tires” of Advancing Oxford Finance Corporation Shows Record Growth in 2007 Eye On Washington

Visions - Winter 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.